Alamar Biosciences, Inc. (ALMR)

Alamar Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Net Income	-29.82	-47.07
Depreciation & Amortization	3.86	3.19
Stock-Based Compensation	2.87	0.87
Other Adjustments	2.05	-0.22
Change in Receivables	-5.91	-4.68
Changes in Inventories	-23.78	-8.75
Changes in Accounts Payable	-0.57	2.92
Changes in Accrued Expenses	6.39	3.49
Changes in Other Operating Activities	-8.69	-4.96
Operating Cash Flow	-53.61	-55.21
Capital Expenditures	-5.37	-2.95
Purchases of Intangible Assets	-1.01	-0.44
Purchases of Investments	-4.94	-92.53
Proceeds from Sale of Investments	57.5	41.98
Investing Cash Flow	46.18	-53.93
Long-Term Debt Issued	10	-
Long-Term Debt Repaid	-	-15
Net Long-Term Debt Issued (Repaid)	10	-15
Issuance of Common Stock	1.49	0.94
Net Common Stock Issued (Repurchased)	1.49	0.94
Issuance of Preferred Stock	-	127.48
Net Preferred Stock Issued (Repurchased)	-	127.48
Other Financing Activities	-0.66	-
Financing Cash Flow	10.84	113.42
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.17	-0
Net Cash Flow	3.23	4.27
Free Cash Flow	-58.98	-58.16
FCF Margin	-79.48%	-231.33%
Free Cash Flow Per Share	-5.11	-4.89
Levered Free Cash Flow	-47.99	-68.33
Unlevered Free Cash Flow	-60.22	-56.64

Updated May 8, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q